Relay’s IPO among the year’s largest for a biotech as others wait in wings

In a year when most new biotech listings have surpassed expectations, Relay’s upsized $400 million IPO is the second-largest yet for a therapeutics developer in 2020.

The clinical developer of precision oncology therapies posted a big aftermarket gain on Thursday, adding 75% after selling 20 million shares at $20, above

Read the full 498 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers